136 related articles for article (PubMed ID: 2868491)
1. Cholecystokinin peptides, dopamine and schizophrenia--a review.
Nair NP; Lal S; Bloom DM
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin-dopamine coexistence: electrophysiological actions corresponding to cholecystokinin receptor subtype.
Hommer DW; Stoner G; Crawley JN; Paul SM; Skirboll LR
J Neurosci; 1986 Oct; 6(10):3039-43. PubMed ID: 3760947
[TBL] [Abstract][Full Text] [Related]
3. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.
Hommer DW; Pickar D; Crawley JN; Weingartner H; Paul SM
Ann N Y Acad Sci; 1985; 448():542-52. PubMed ID: 3896099
[TBL] [Abstract][Full Text] [Related]
4. In vivo sulfation of cholecystokinin octapeptide. Possible interactions of the two forms of cholecystokinin with dopamine in the brain.
Penke B; Kovács GL; Zsigó J; Kádár T; Szabó G; Kovács K; Telegdy G
Ann N Y Acad Sci; 1985; 448():293-305. PubMed ID: 2862826
[TBL] [Abstract][Full Text] [Related]
5. Two faces of cholecystokinin: anxiety and schizophrenia.
Bourin M; Malinge M; Vasar E; Bradwejn J
Fundam Clin Pharmacol; 1996; 10(2):116-26. PubMed ID: 8737954
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin-dopamine receptor interactions as studied with cholecystokinin receptor antagonists.
Murphy RB
Prog Clin Biol Res; 1985; 192():105-13. PubMed ID: 3001746
[TBL] [Abstract][Full Text] [Related]
7. Evidence for cholecystokinin-dopamine receptor interactions in the central nervous system of the adult and old rat. Studies on their functional meaning.
Agnati LF; Fuxe K; Giardino L; Calza L; Zoli M; Battistini N; Benfenati F; Vanderhaeghen JJ; Guidolin D; Ruggeri M
Ann N Y Acad Sci; 1985; 448():315-33. PubMed ID: 2862827
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
Feifel D; Reza T; Robeck S
Neuropsychopharmacology; 1999 Feb; 20(2):141-9. PubMed ID: 9885794
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptics, dopamine, and schizophrenia.
Pickar D
Psychiatr Clin North Am; 1986 Mar; 9(1):35-48. PubMed ID: 2870480
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man.
Lal S; Nair NP; Eugenio H; Thavundayil J; Lizondo E; Wood PL; Etienne P; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):537-44. PubMed ID: 6320299
[TBL] [Abstract][Full Text] [Related]
11. Release of cholecystokinin from rat midbrain slices and modulatory effect of D2DA receptor stimulation.
Freeman AS; Chiodo LA; Lentz SI; Wade K; Bannon MJ
Brain Res; 1991 Aug; 555(2):281-7. PubMed ID: 1682000
[TBL] [Abstract][Full Text] [Related]
12. Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro.
Brodie MS; Dunwiddie TV
Brain Res; 1987 Nov; 425(1):106-13. PubMed ID: 3427413
[TBL] [Abstract][Full Text] [Related]
13. Effects of cholecystokinin octapeptide on striatal dopamine metabolism and on apomorphine-induced stereotyped cage-climbing in mice.
Kovács GL; Szabó G; Penke B; Telegdy G
Eur J Pharmacol; 1981 Jan; 69(3):313-9. PubMed ID: 6260512
[TBL] [Abstract][Full Text] [Related]
14. Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons.
White FJ; Wang RY
Brain Res; 1984 May; 300(1):161-6. PubMed ID: 6145498
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58.
Fuxe K; Agnati LF; Vanderhaeghen JJ; Tatemoto K; Andersson K; Eneroth P; Härfstrand A; Von Euler G; Toni R; Goldstein M
Ann N Y Acad Sci; 1985; 448():231-54. PubMed ID: 2862825
[TBL] [Abstract][Full Text] [Related]
16. Increased neuronal responsiveness to cholecystokinin and dopamine induced by lesioning mesolimbic dopaminergic neurons: an electrophysiological study in the rat.
Debonnel G; de Montigny C
Synapse; 1988; 2(5):537-45. PubMed ID: 2903570
[TBL] [Abstract][Full Text] [Related]
17. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.
Loonam TM; Noailles PA; Yu J; Zhu JP; Angulo JA
Life Sci; 2003 Jun; 73(6):727-39. PubMed ID: 12801594
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.
Rasmussen K; Czachura JF; Stockton ME; Howbert JJ
J Pharmacol Exp Ther; 1993 Jan; 264(1):480-8. PubMed ID: 8423546
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic agents affected neuronal transmission of cholecystokinin in the rat brain.
Fukamauchi F; Yoshikawa T; Kaneno S; Shibuya H; Takahashi R
Neuropeptides; 1987 Oct; 10(3):207-20. PubMed ID: 2825061
[TBL] [Abstract][Full Text] [Related]
20. The effects of ceruletide in schizophrenia.
Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
